Study: NCT00482053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Description: Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Description: Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Description: TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV days 1 and 7 over 4 to 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: 1.5 mg/kg/day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5.0 mg/kg twice daily from day -3 until after day +56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 100 mg/kg will be administered over 2 hours on day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7